115 related articles for article (PubMed ID: 24433863)
1. Heteroarylureas with spirocyclic diamine cores as inhibitors of fatty acid amide hydrolase.
Keith JM; Jones WM; Pierce JM; Seierstad M; Palmer JA; Webb M; Karbarz MJ; Scott BP; Wilson SJ; Luo L; Wennerholm ML; Chang L; Brown SM; Rizzolio M; Rynberg R; Chaplan SR; Breitenbucher JG
Bioorg Med Chem Lett; 2014 Feb; 24(3):737-41. PubMed ID: 24433863
[TBL] [Abstract][Full Text] [Related]
2. Heteroarylureas with fused bicyclic diamine cores as inhibitors of fatty acid amide hydrolase.
Keith JM; Jones W; Pierce JM; Seierstad M; Palmer JA; Webb M; Karbarz M; Scott BP; Wilson SJ; Luo L; Wennerholm M; Chang L; Rizzolio M; Rynberg R; Chaplan S; Guy Breitenbucher J
Bioorg Med Chem Lett; 2020 Oct; 30(20):127463. PubMed ID: 32784090
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 2. Discovery of 7-azaspiro[3.5]nonane urea PF-04862853, an orally efficacious inhibitor of fatty acid amide hydrolase (FAAH) for pain.
Meyers MJ; Long SA; Pelc MJ; Wang JL; Bowen SJ; Schweitzer BA; Wilcox MV; McDonald J; Smith SE; Foltin S; Rumsey J; Yang YS; Walker MC; Kamtekar S; Beidler D; Thorarensen A
Bioorg Med Chem Lett; 2011 Nov; 21(21):6545-53. PubMed ID: 21924613
[TBL] [Abstract][Full Text] [Related]
4. Identification of potent, noncovalent fatty acid amide hydrolase (FAAH) inhibitors.
Gustin DJ; Ma Z; Min X; Li Y; Hedberg C; Guimaraes C; Porter AC; Lindstrom M; Lester-Zeiner D; Xu G; Carlson TJ; Xiao S; Meleza C; Connors R; Wang Z; Kayser F
Bioorg Med Chem Lett; 2011 Apr; 21(8):2492-6. PubMed ID: 21392988
[TBL] [Abstract][Full Text] [Related]
5. Validation and application of an LC-MS/MS method for quantitation of three fatty acid ethanolamides as biomarkers for fatty acid hydrolase inhibition in human plasma.
Jian W; Edom R; Weng N; Zannikos P; Zhang Z; Wang H
J Chromatogr B Analyt Technol Biomed Life Sci; 2010 Jun; 878(20):1687-99. PubMed ID: 20462810
[TBL] [Abstract][Full Text] [Related]
6. Structure based design of novel irreversible FAAH inhibitors.
Wang JL; Bowen SJ; Schweitzer BA; Madsen HM; McDonald J; Pelc MJ; Tenbrink RE; Beidler D; Thorarensen A
Bioorg Med Chem Lett; 2009 Oct; 19(20):5970-4. PubMed ID: 19765986
[TBL] [Abstract][Full Text] [Related]
7. Discovery of novel spirocyclic inhibitors of fatty acid amide hydrolase (FAAH). Part 1: identification of 7-azaspiro[3.5]nonane and 1-oxa-8-azaspiro[4.5]decane as lead scaffolds.
Meyers MJ; Long SA; Pelc MJ; Wang JL; Bowen SJ; Walker MC; Schweitzer BA; Madsen HM; Tenbrink RE; McDonald J; Smith SE; Foltin S; Beidler D; Thorarensen A
Bioorg Med Chem Lett; 2011 Nov; 21(21):6538-44. PubMed ID: 21924614
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid amide hydrolase inhibitors. 3: tetra-substituted azetidine ureas with in vivo activity.
Roughley SD; Browne H; Macias AT; Benwell K; Brooks T; D'Alessandro J; Daniels Z; Dugdale S; Francis G; Gibbons B; Hart T; Haymes T; Kennett G; Lightowler S; Matassova N; Mansell H; Merrett A; Misra A; Padfield A; Parsons R; Pratt R; Robertson A; Simmonite H; Tan K; Walls SB; Wong M
Bioorg Med Chem Lett; 2012 Jan; 22(2):901-6. PubMed ID: 22209458
[TBL] [Abstract][Full Text] [Related]
9. Heteroaryl urea inhibitors of fatty acid amide hydrolase: structure-mutagenicity relationships for arylamine metabolites.
Tichenor MS; Keith JM; Jones WM; Pierce JM; Merit J; Hawryluk N; Seierstad M; Palmer JA; Webb M; Karbarz MJ; Wilson SJ; Wennerholm ML; Woestenborghs F; Beerens D; Luo L; Brown SM; Boeck MD; Chaplan SR; Breitenbucher JG
Bioorg Med Chem Lett; 2012 Dec; 22(24):7357-62. PubMed ID: 23141911
[TBL] [Abstract][Full Text] [Related]
10. Thiadiazolopiperazinyl ureas as inhibitors of fatty acid amide hydrolase.
Keith JM; Apodaca R; Xiao W; Seierstad M; Pattabiraman K; Wu J; Webb M; Karbarz MJ; Brown S; Wilson S; Scott B; Tham CS; Luo L; Palmer J; Wennerholm M; Chaplan S; Breitenbucher JG
Bioorg Med Chem Lett; 2008 Sep; 18(17):4838-43. PubMed ID: 18693015
[TBL] [Abstract][Full Text] [Related]
11. Fatty acid amide hydrolase inhibitors. Surprising selectivity of chiral azetidine ureas.
Hart T; Macias AT; Benwell K; Brooks T; D'Alessandro J; Dokurno P; Francis G; Gibbons B; Haymes T; Kennett G; Lightowler S; Mansell H; Matassova N; Misra A; Padfield A; Parsons R; Pratt R; Robertson A; Walls S; Wong M; Roughley S
Bioorg Med Chem Lett; 2009 Aug; 19(15):4241-4. PubMed ID: 19515560
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.
Kono M; Matsumoto T; Imaeda T; Kawamura T; Fujimoto S; Kosugi Y; Odani T; Shimizu Y; Matsui H; Shimojo M; Kori M
Bioorg Med Chem; 2014 Feb; 22(4):1468-78. PubMed ID: 24440478
[TBL] [Abstract][Full Text] [Related]
13. The SAR of brain penetration for a series of heteroaryl urea FAAH inhibitors.
Keith JM; Tichenor MS; Apodaca RL; Xiao W; Jones WM; Seierstad M; Pierce JM; Palmer JA; Webb M; Karbarz MJ; Scott BP; Wilson SJ; Wennerholm ML; Rizzolio M; Rynberg R; Chaplan SR; Breitenbucher JG
Bioorg Med Chem Lett; 2016 Jul; 26(13):3109-3114. PubMed ID: 27189675
[TBL] [Abstract][Full Text] [Related]
14. (4-Phenoxyphenyl)tetrazolecarboxamides and related compounds as dual inhibitors of fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL).
Holtfrerich A; Hanekamp W; Lehr M
Eur J Med Chem; 2013 May; 63():64-75. PubMed ID: 23455058
[TBL] [Abstract][Full Text] [Related]
15. Aryl Piperazinyl Ureas as Inhibitors of Fatty Acid Amide Hydrolase (FAAH) in Rat, Dog, and Primate.
Keith JM; Apodaca R; Tichenor M; Xiao W; Jones W; Pierce J; Seierstad M; Palmer J; Webb M; Karbarz M; Scott B; Wilson S; Luo L; Wennerholm M; Chang L; Brown S; Rizzolio M; Rynberg R; Chaplan S; Breitenbucher JG
ACS Med Chem Lett; 2012 Oct; 3(10):823-7. PubMed ID: 24900385
[TBL] [Abstract][Full Text] [Related]
16. Preclinical Characterization of the FAAH Inhibitor JNJ-42165279.
Keith JM; Jones WM; Tichenor M; Liu J; Seierstad M; Palmer JA; Webb M; Karbarz M; Scott BP; Wilson SJ; Luo L; Wennerholm ML; Chang L; Rizzolio M; Rynberg R; Chaplan SR; Breitenbucher JG
ACS Med Chem Lett; 2015 Dec; 6(12):1204-8. PubMed ID: 26713105
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and preliminary evaluation of a novel positron emission tomography (PET) ligand for imaging fatty acid amide hydrolase (FAAH).
Chen Z; Hou L; Gan J; Cai Q; Ye W; Chen J; Tan Z; Zheng C; Li G; Xu H; Fowler CJ; Liang SH; Wang L
Bioorg Med Chem Lett; 2020 Nov; 30(21):127513. PubMed ID: 32860981
[TBL] [Abstract][Full Text] [Related]
18. 1-Indol-1-yl-propan-2-ones and related heterocyclic compounds as dual inhibitors of cytosolic phospholipase A(2)alpha and fatty acid amide hydrolase.
Forster L; Ludwig J; Kaptur M; Bovens S; Elfringhoff AS; Holtfrerich A; Lehr M
Bioorg Med Chem; 2010 Jan; 18(2):945-52. PubMed ID: 20005725
[TBL] [Abstract][Full Text] [Related]
19. Elucidation of fatty acid amide hydrolase inhibition by potent alpha-ketoheterocycle derivatives from Monte Carlo simulations.
Guimarães CR; Boger DL; Jorgensen WL
J Am Chem Soc; 2005 Dec; 127(49):17377-84. PubMed ID: 16332087
[TBL] [Abstract][Full Text] [Related]
20. The putative endocannabinoid transport blocker LY2183240 is a potent inhibitor of FAAH and several other brain serine hydrolases.
Alexander JP; Cravatt BF
J Am Chem Soc; 2006 Aug; 128(30):9699-704. PubMed ID: 16866524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
